Results 91 to 100 of about 131,343 (196)

A new Korean nomenclature for steatotic liver disease [PDF]

Clinical and Molecular Hepatology
Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
doaj   +3 more sources

Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? [PDF]

, 2018
Introduction: Non-alcoholic fatty liver disease (NAFLD), considered the leading cause of chronic liver disease in children, can often progress from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).
Alisi, A, Chierico, Fd, Cucchiara, S, Drago, Lorenzo, Mosca, A, Nobili, V, Putignani, L, Stronati, L, Toscano, M, Vernocchi, P   +9 more
core   +3 more sources

Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. [PDF]

, 2014
The current dogma is that obesity-associated hepatic inflammation is due to increased Kupffer cell (KC) activation. However, recruited hepatic macrophages (RHMs) were recently shown to represent a sizable liver macrophage population in the context of ...
Bandyopadhyay, Gautam, Bogner-Strauss, Juliane G, Chi, Tyler J, Chung, Heekyung, Evans, Ronald M, Franck, Niclas, Hah, Nasun, Heinrichsdorff, Jan, Mayoral, Rafael, Morinaga, Hidetaka, Oh, Da Young, Olefsky, Jerrold M, Osborn, Olivia, Pessentheiner, Ariane R, Walenta, Evelyn   +14 more
core   +2 more sources

The Role of Omega-3 Fatty Acids on the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: A Review of Published Papers

مجله دانشکده پزشکی اصفهان, 2014
Background: 10 to 35% of the adult population all round the world is infected with nonalcoholic fatty liver disease (NAFLD). So far, no cure is recommended for this disease.
Hamid Zolfaghari, Kourosh Jafarian, Bijhan Iraj, Gholamreza Askari   +3 more
doaj  

Treating hepatic steatosis and fibrosis by modulating mitochondrial pyruvate metabolism [PDF]

, 2019
A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes.
Finck, Brian N, McCommis, Kyle S
core   +2 more sources

The effectiveness of metformin in patients with metabolic syndrome and nonalcoholic fatty liver disease

Ожирение и метаболизм, 2008
The mechanism of action of metformin is realized through activation of cAMP-dependent protein kinase, leading to a decrease hepatic glucose production as well as to decrease the synthesis of triglycerides and an increase in fat oxidation. Several studies
S A Butrova, A Yu Eliseeva, A V Il'in
doaj   +1 more source

Metabolic effects of ursodeoxycholic acid in patients with non-alcoholic fatty liver disease

Лечащий Врач
Background. Nonalcoholic fatty liver disease is by far the most common chronic liver disease worldwide with a global prevalence of 32.4%. Currently, there is an active search for new therapeutic options for the management of patients with nonalcoholic ...
V. A. Akhmedov
doaj   +1 more source

Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes

Journal of Obesity & Metabolic Syndrome, 2018
Background : Vitamin D deficiency is known to increase the incidence of metabolic syndrome. Nonalcoholic fatty liver disease is a common metabolic disease in patients with type 2 diabetes.
Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung Koo Kang, Bo-Yeon Kim   +5 more
doaj   +1 more source

Polypill for prevention of cardiovascular disease in an Urban Iranian population with special focus on nonalcoholic steatohepatitis: A pragmatic randomized controlled trial within a cohort (PolyIran - Liver) – Study protocol [PDF]

, 2015
Background: Cardiovascular disease (CVD) is among the most common causes of mortality in all populations. Nonalcoholic steatohepatitis is a common finding in patients with CVD. Prevention of CVD in individual patients typically requires periodic clinical
Hemming, K., Jafari, E., Khoshnia, M., Khuzani, A.S., Malekzadeh, R., Marshall, T., Merat, S., Nateghi, A., Poustchi, H., Radmard, A.-R.   +9 more
core  

Gut microbiota regulates serum metabolites in mice with nonalcoholic fatty liver disease via gut metabolites: mechanisms involving branched-chain amino acids and unsaturated fatty acids

Frontiers in Endocrinology
IntroductionIn recent years, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease globally. Studies indicate that the gut-liver axis plays an important role in the occurrence and development of this disease.
Hao Qiu, Hao Qiu, Yuhang Wen, Yuhang Wen, Yadan Luo, Yadan Luo, Shuya Lv, Shuya Lv, Jingrong Huang, Jingrong Huang, Baoting Chen, Baoting Chen, Ruilin Lu, Ruilin Lu, Lvqin He, Lvqin He, Qian Yang, Qian Yang, Jianhong Han, Jianhong Han, Xuefeng Yan, Xuefeng Yan, Manli He, Manli He, Mingde Zhao, Mingde Zhao, Xiaoxia Zou, Xiaoxia Zou, Congwei Gu, Congwei Gu, Congwei Gu   +30 more
doaj   +1 more source